Hemophilia Therapy and Blood-Borne Pathogen Risk

ABSTRACT

For a brief period, modern medical science was considered to have relegated infectious disease to that of a minor clinical challenge. However, several infectious diseases have emerged or re-emerged in recent years, raising epidemiological concerns, as well as issues over the availability of effective measures of control and treatment. Invariably, these infectious agents have been studied carefully in relation to the safety of blood products, often resulting in concern and action. Emerging diseases arise from many sources. Some are the result of viruses crossing the species barrier from animals to humans. In addition, combinations of these newly identified viruses may make each more difficult to treat, as in the case of human immunodeficiency virus and hepatitis C virus coinfection. Still others can arise from completely new biological mechanisms, such as the prion disease variant Creutzfeldt-Jacob disease, which has spread from infected cattle to humans, particularly in the United Kingdom. The emergence of new viruses and new disease sources has had a significant impact on coagulation factor therapies and blood donation policies. We must deal with these multiple threats and their potential to compromise the safety of our blood supply.

KEYWORDS

Emerging diseases - blood safety - variant Creutzfeldt-Jacob disease (vCJD) - blood transmission

REFERENCES

• 1 Johnson R T. Emerging viral infections of the nervous system.  J Neurovirol. 2003;  9 140-147
• 2 Appel M J, Scott F W, Carmichael L E. Isolation and immunisation studies of a canine parvo-like virus from dogs with haemorrhagic enteritis.  Vet Rec. 1979;  105 156-159
• 3 Chong H T, Kunjapan S R, Thayaparan T et al.. Nipah encephalitis outbreak in Malaysia, clinical features in patients from Seremban.  Can J Neurol Sci. 2002;  29 83-87
• 4 Tan C T, Goh K J, Wong K T et al.. Relapsed and late-onset Nipah encephalitis.  Ann Neurol. 2002;  51 703-708
• 5 Chua K B, Goh K J, Wong K T et al.. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.  Lancet. 1999;  354 1257-1259
• 6 WHO .Nipah Virus. Fact Sheet Number 262. Revised. Geneva, Switzerland; World Health Organization September 2001
• 7 Tan C T, Wong K T. Nipah encephalitis outbreak in Malaysia.  Ann Acad Med Singapore. 2003;  32 112-117
• 8 Ai S Y. Profile of a virus. http://Available at: http:agrolink.moa.my/jph/dvs/nipah/star000410/nipah-profile.html Accessed October 3, 2005
• 9 Buonavoglia C, Martella V, Pratelli A et al.. Evidence for evolution of canine parvovirus type 2 in Italy.  J Gen Virol. 2001;  82 3021-3025
• 10 Cohen B. Parvovirus B19: an expanding spectrum of disease.  BMJ. 1995;  311 1549-1552
• 11 Steinel A, Parrish C R, Bloom M E, Truyen U. Parvovirus infections in wild carnivores.  J Wildl Dis. 2001;  37 594-607
• 12 Heegaard E D, Brown K E. Human parvovirus B19.  Clin Microbiol Rev. 2002;  15 485-505
• 13 Santagostino E, Mannucci P M, Gringeri A et al.. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.  Transfusion. 1997;  37 517-522
• 14 Croghan D L, Matchett A, Koski T A. Isolation of porcine parvovirus from commercial trypsin.  Appl Microbiol. 1973;  26 431-433
• 15 Blumel J, Schmidt I, Effenberger W et al.. Parvovirus B19 transmission by heat-treated clotting factor concentrates.  Transfusion. 2002;  42 1473-1481
• 16 Wu C G, Mason B, Jong J et al.. Parvovirus B19 transmission by a high-purity factor VIII concentrate.  Transfusion. 2005;  45 1003-1010
• 17 Chae C. A review of porcine circovirus 2-associated syndromes and diseases.  Vet J. 2005;  169 326-336
• 18 Miller M M, Schat K A. Chicken infectious anemia virus: an example of the ultimate host-parasite relationship.  Avian Dis. 2004;  48 734-745
• 19 Bendinelli M, Pistello M, Maggi F et al.. Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans.  Clin Microbiol Rev. 2001;  14 98-113
• 20 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.  Clin Infect Dis. 2001;  33 562-569
• 21 Greub G, Ledergerber B, Battegay M et al.. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.  Lancet. 2000;  356 1800-1805
• 22 Beers M H, Berkow R B. The Merck Manual of Diagnosis and Therapy. Section 13, Chapter 163. Human immunodeficiency virus infection. Merck & Co. Available at: http://www.merck.com/mrkshared/mmanuel/home.jsp Accessed June 1, 2005
• 23 Canavese C, Hollo Z, Ciccone G et al.. Extrahepatic immunological manifestations of hepatitis C virus in dialysis patients.  J Nephrol. 2000;  13 352-359
• 24 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med. 1999;  341 556-562
• 25 Melvin D C, Lee J K, Belsey E, Arnold J, Murphy R L. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy.  AIDS. 2000;  14 463-465
• 26 Palella Jr F J, Delaney K M, Moorman A C et al.. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.  N Engl J Med. 1998;  338 853-860
• 27 Darby S C, Ewart D W, Giangrande P L et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.  Lancet. 1997;  350 1425-1431
• 28 Torriani F J, Rodriguez-Torres M, Rockstroh J K et al.. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.  N Engl J Med. 2004;  351 438-450
• 29 Beisel C E, Morens D M. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies.  Clin Infect Dis. 2004;  38 697-704
• 30 Brown P, Will R G, Bradley R, Asher D M, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.  Emerg Infect Dis. 2001;  7 6-16
• 31 Will R G, Ironside J W, Zeidler M et al.. A new variant of Creutzfeldt-Jakob disease in the UK.  Lancet. 1996;  347 921-925
• 32 NCJDSU .The National Creutzfeldt-Jakob Disease Surveillance Unit. CJD statistics. Available at: http://www.cjd.ed.ac.uk/figures.htm Accessed October 3, 2005
• 33 Peden A H, Head M W, Ritchie D L, Bell J E, Ironside J W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.  Lancet. 2004;  364 527-529
• 34 Ghani A C, Donnelly C A, Ferguson N M, Anderson R M. Updated projections of future vCJD deaths in the UK.  BMC Infect Dis. 2003;  3 4
• 35 Nix P. Prions and disposable surgical instruments.  Int J Clin Pract. 2003;  57 678-680
• 36 Houston F, Foster J D, Chong A, Hunter N, Bostock C J. Transmission of BSE by blood transfusion in sheep.  Lancet. 2000;  356 999-1000
• 37 Llewelyn C A, Hewitt P E, Knight R S et al.. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.  Lancet. 2004;  363 417-421
• 38 Sachse C, Groschup M H, Warzok R, Greinacher A. Role of variant Creutzfeldt-Jakob disease for safety of treatment with blood components: screening of lymphatic tissue is a potential tool for risk assessment.  Eur J Haematol. 2003;  70 11-16
• 39 Brown P, Rohwer R G, Dunstan B C et al.. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy.  Transfusion. 1998;  38 810-816
• 40 Hunter N, Foster J, Chong A et al.. Transmission of prion diseases by blood transfusion.  J Gen Virol. 2002;  83 2897-2905
• 41 Communicable Disease Report Weekly . New case of transfusion-associated variant-CJD.  CDR Weekly. 2006;  9(Feb) 1
• 42 Ironside J W. The spectrum of safety: variant Creutzfeldt-Jakob disease in the United Kingdom.  Semin Hematol. 2003;  40 16-22
• 43 UKHCDO . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.  Haemophilia. 2003;  9 1-23